journal
MENU ▼
Read by QxMD icon Read
search

Therapeutic Advances in Gastroenterology

journal
https://www.readbyqxmd.com/read/30397412/insights-into-the-evaluation-and-management-of-dyspepsia-recent-developments-and-new-guidelines
#1
REVIEW
Christopher J Black, Lesley A Houghton, Alexander C Ford
Dyspepsia is a very common gastrointestinal (GI) condition worldwide. We critically examine the recommendations of recently published guidelines for the management of dyspepsia, including those produced jointly by the American College of Gastroenterology and the Canadian Association of Gastroenterology, and those published by the UK National Institute for Health and Care Excellence. Dyspepsia is a symptom complex, characterized by a range of upper GI symptoms including epigastric pain or burning, early satiety, and post-prandial fullness...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30377451/current-frontline-approaches-in-the-management-of-hepatocellular-carcinoma-the-evolving-role-of-immunotherapy
#2
REVIEW
Gagandeep Brar, Tim F Greten, Zachary J Brown
Hepatocellular carcinoma (HCC) is a major cause of cancer-associated mortality worldwide and is expected to rise. Patients with early-stage disease may have a good prognosis with a 5-year survival rate of greater than 70%. However, the majority of patients are diagnosed with late-stage disease with a dismal overall survival rate of less than 16%. Therefore, there is a great need for advances in the treatment of advanced HCC, which for approximately the past decade, has been sorafenib. Immunotherapy is an evolving cancer treatment and has shown promise in treating patients with advanced HCC...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30364471/glp-2-analog-teduglutide-significantly-reduces-need-for-parenteral-nutrition-and-stool-frequency-in-a-real-life-setting
#3
Marc Schoeler, Thomas Klag, Judith Wendler, Simon Bernhard, Michael Adolph, Andreas Kirschniak, Martin Goetz, Nisar Malek, Jan Wehkamp
Background: To evaluate the benefits of teduglutide in a real-life setting, we analyzed the data of 14 patients with short bowel syndrome treated with teduglutide. Additionally, we studied glucagon-like peptide 2 (GLP-2) receptor expression in samples of small intestinal and colonic tissue to provide explanations for clinical observations. Methods: Stool frequency and consistency, sensation of thirst, parental calorie or fluid uptake and the number of days on parenteral support per week were collected for up to 2 years...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30344642/switching-from-originator-infliximab-to-the-biosimilar-ct-p13-in-313-patients-with-inflammatory-bowel-disease
#4
Viktoria Bergqvist, Mohammad Kadivar, Daniel Molin, Leif Angelison, Per Hammarlund, Marie Olin, Jörgen Torp, Olof Grip, Stefan Nilson, Erik Hertervig, Jan Lillienau, Jan Marsal
Background: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD). However, published switch studies of the first infliximab biosimilar, CT-P13, have delivered ambiguous results that could be interpreted as showing a trend towards inferior effectiveness in Crohn's disease (CD) compared with ulcerative colitis (UC). The aim of this study was to investigate the effectiveness and safety of switching IBD patients from treatment with Remicade to CT-P13...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30305847/cost-effectiveness-of-sacral-nerve-stimulation-and-percutaneous-tibial-nerve-stimulation-for-faecal-incontinence
#5
Natalia Hounsome, Chris Roukas
Background: Subcutaneous sacral nerve stimulation is recommended by the United Kingdom (UK) National Institute for Health and Care Excellence (NICE) as a second-line treatment for patients with faecal incontinence who failed conservative therapy. Sacral nerve stimulation is an invasive procedure associated with complications and reoperations. This study aimed to investigate whether delivering less invasive and less costly percutaneous tibial nerve stimulation prior to sacral nerve stimulation is cost-effective...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30302127/drug-holiday-in-patients-with-polycystic-liver-disease-treated-with-somatostatin-analogues
#6
René M M van Aerts, Marieke Kolkman, Wietske Kievit, Tom J G Gevers, Frederik Nevens, Joost P H Drenth
Background: Somatostatin analogues (SAs) reduce liver volume and relief symptoms in polycystic liver disease (PLD). Its effect wears off after continuing therapy suggesting development of SA tolerance in patients on chronic therapy. We postulate that a drug holiday resensitizes the liver to its acute pharmacological effects. Therefore, this study examines the liver volume-reducing effect of SAs after a drug holiday. Methods: Patients were identified from the International PLD Registry and included in our analysis when (1) treated with SAs during two cycles separated by a drug holiday and (2) height-adjusted total liver volume (hTLV) was available at start and end of each cycle...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30302126/food-and-drug-administration-guidances-on-biosimilars-an-update-for-the-gastroenterologist
#7
REVIEW
Michael Epstein
The management of inflammatory bowel disease (IBD), a significant cause of morbidity in the United States (US), has been revolutionized over the last two decades by the introduction of biologic therapies. These include antitumor necrosis factor α (TNF-α) agents. Since 2016, five biosimilar TNF-α inhibitors have been approved by the US Food and Drug Administration (FDA) for use in the treatment of IBD. The FDA has published a series of guidance documents related to the evaluation, licensing, and approval of biosimilars...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30302125/uk-clinical-experience-up-to-52-weeks-with-linaclotide-for-irritable-bowel-syndrome-with-constipation
#8
Yan Yiannakou, Anu Agrawal, Patrick B Allen, Naila Arebi, Steven R Brown, Maria P Eugenicos, Adam D Farmer, Su McLain-Smith, John McLaughlin, David S Sanders, Dominic Lawrance, Anton Emmanuel
Background: Linaclotide, a guanylate cyclase C agonist, has been shown in clinical trials to improve symptoms of irritable bowel syndrome with constipation (IBS-C). Here we report data from a real-world study of linaclotide in the UK. Methods: This 1-year, multicentre, prospective, observational study in the UK enrolled patients aged 18 years and over initiating linaclotide for IBS-C. The primary assessment was change from baseline in IBS Symptom Severity Scale (IBS-SSS) score at 12 weeks, assessed in patients with paired baseline and 12-week data...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30283499/rifaximin-has-the-potential-to-prevent-complications-of-cirrhosis
#9
Steven L Flamm, Kevin D Mullen, Zeev Heimanson, Arun J Sanyal
Background: Cirrhosis-related complications are associated with poor prognosis. With our analyses, we examined the potential benefit of rifaximin in reducing the risk of developing cirrhosis-related complications. Methods: Adults with cirrhosis and hepatic encephalopathy (HE) in remission were randomly assigned to receive rifaximin 550 mg twice daily or placebo for 6 months with concomitant lactulose permitted. Post hoc analyses examined time to cirrhosis-related complications (HE, spontaneous bacterial peritonitis (SBP), variceal bleeding, acute kidney injury/hepatorenal syndrome)...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30263065/the-performance-of-remicade%C3%A2-optimized-quantification-assays-in-the-assessment-of-flixabi%C3%A2-levels
#10
F Magro, C Rocha, A I Vieira, H T Sousa, I Rosa, S Lopes, J Carvalho, C C Dias, J Afonso
Background: The advent of Remicade® biosimilars, Remsima®, Inflectra® and, more recently, Flixabi®, has brought along the potential to decrease the costs associated with this therapy, therefore increasing its access to a larger group of patients. However, and in order to assure a soft transition, one must make sure the assays and algorithms previously developed and optimized for Remicade perform equally well with its biosimilars. This study aimed to: (a) validate the utilization of Remicade-optimized therapeutic drug monitoring assays for the quantification of Flixabi; and (b) determine the existence of Remicade, Remsima and Flixabi cross-immunogenicity...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30228831/fatigue-and-its-associated-factors-in-microscopic-colitis
#11
John S Kane, Andrew J Irvine, Yannick Derwa, Alexander C Ford
Background: Fatigue is a well-recognized symptom in patients with inflammatory bowel disease and irritable bowel syndrome (IBS), and has been associated with psychological comorbidity and impaired quality of life in both. However, features associated with fatigue in patients with microscopic colitis (MC) are less clear. Materials and methods: We conducted a cross-sectional survey of patients with a new diagnosis of MC including levels of anxiety, depression, somatization, quality of life, and IBS-type symptoms...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30202445/anticoagulant-therapy-in-patients-with-liver-cirrhosis-and-portal-vein-thrombosis-insights-for-the-clinician
#12
REVIEW
Stefania Basili, Daniele Pastori, Valeria Raparelli, Francesco Violi
Portal vein thrombosis (PVT) is a frequent complication in the natural history of patients with liver cirrhosis (LC). The prevalence of PVT in LC is highly variable, ranging from 0.6% to 25% according to different reports. The impact of PVT on the natural history of LC is unclear, but it seems to negatively affect the prognosis of patients undergoing liver transplantation (LT) by increasing post-LT mortality and delaying waiting time. The antithrombotic treatment of PVT is still challenging as PVT may often remain asymptomatic and incidentally diagnosed, and a spontaneous partial/total regression of PVT is observed in an important proportion of patients, even in the absence of anticoagulation...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30159037/indoleamine-2-3-dioxygenase-dependent-expansion-of-t-regulatory-cells-maintains-mucosal-healing-in-ulcerative-colitis
#13
Aleksandar Acovic, Bojana Simovic Markovic, Marina Gazdic, Aleksandar Arsenijevic, Nemanja Jovicic, Nevena Gajovic, Marina Jovanovic, Natasa Zdravkovic, Tatjana Kanjevac, C Randall Harrell, Crissy Fellabaum, Zana Dolicanin, Valentin Djonov, Nebojsa Arsenijevic, Miodrag L Lukic, Vladislav Volarevic
Background: Dendritic cell (DC)-derived indolamine 2,3-dioxygenase (IDO) degrades tryptophan to kynurenine, which promotes conversion of inflammatory T cells in immunosuppressive regulatory T cells (Tregs). We analyzed the significance of the IDO:Treg axis for inducing and maintaining mucosal healing in ulcerative colitis (UC). Methods: Dextran sodium sulphate (DSS)-induced colitis in BALB/c mice (model for mucosal healing) and C57BL/6 mice (model for persistent disease) was used...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30159036/increasing-trend-in-admission-rates-and-costs-for-acute-diverticulitis-during-2005-2015-real-life-data-from-the-abruzzo-region
#14
Simona Cammarota, Martina Cargiolli, Paolo Andreozzi, Bernardo Toraldo, Anna Citarella, Maria Elena Flacco, Gian Andrea Binda, Bruno Annibale, Lamberto Manzoli, Rosario Cuomo
Background: Scarce data are available on the epidemiological trend of diverticulitis and its financial burden in Italy. The aim of this work was to explore a potential variation in the rate and costs of hospital admissions for uncomplicated and complicated diverticulitis over the last decade. Methods: We selected all hospitalizations for diverticulitis of residents in the Abruzzo Region, Italy between 2005 and 2015. Age-standardized hospitalization rates (HRs) per 100,000 inhabitants for overall, uncomplicated and complicated diverticulitis were calculated...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30159035/cholestatic-liver-diseases-new-targets-new-therapies
#15
REVIEW
Priscila Santiago, Andrew R Scheinberg, Cynthia Levy
Cholestatic liver diseases result from gradual destruction of bile ducts, accumulation of bile acids and self-perpetuation of the inflammatory process leading to damage to cholangiocytes and hepatocytes. If left untreated, cholestasis will lead to fibrosis, biliary cirrhosis, and ultimately end-stage liver disease. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) are the two most common chronic cholestatic liver diseases affecting adults, and their etiologies remain puzzling. While treatment with ursodeoxycholic acid (UDCA) has significantly improved outcomes and prolonged transplant-free survival for patients with PBC, treatment options for UDCA nonresponders remain limited...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30046356/progress-and-challenges-in-the-management-of-diverticular-disease-which-treatment
#16
REVIEW
Angel Lanas, Daniel Abad-Baroja, Aitor Lanas-Gimeno
Diverticular disease of the colon (DDC) includes a spectrum of conditions from asymptomatic diverticulosis to symptomatic uncomplicated diverticulosis, segmental colitis associated with diverticulosis, and acute diverticulitis without or with complications that may have serious consequences. Clinical and scientific interest in DDC is increasing because of the rising incidence of all conditions within the DDC spectrum, a better, although still limited understanding of the pathogenic mechanisms involved; the increasing socioeconomic burden; and the new therapeutic options being tested...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30034534/management-of-occult-obscure-gastrointestinal-bleeding-patients-based-on-long-term-outcomes
#17
Sayoko Kunihara, Shiro Oka, Shinji Tanaka, Akiyoshi Tsuboi, Ichiro Otani, Kazuaki Chayama
Background: There is no consensus regarding the management of occult obscure gastrointestinal bleeding (OGIB) patients without a confirmed bleeding source. This study aimed to consider the management of occult OGIB patients based on their long-term outcomes. Methods: We retrospectively enrolled 357 consecutive occult OGIB patients (203 men; mean age: 59.7 years) who underwent capsule endoscopy (CE) at Hiroshima University Hospital, Japan and were followed up for more than 12 months (mean follow-up period; 50...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30034533/the-short-term-effects-of-posterior-tibial-nerve-stimulation-on-anorectal-physiology-in-patients-with-faecal-incontinence-a-single-centre-experience
#18
Nick A Heywood, James S Pearson, James E Nicholson, Clare Molyneux, Abhiram Sharma, Edward S Kiff, Peter J Whorwell, Karen J Telford
Background: Posterior tibial nerve stimulation (PTNS) is a novel treatment for patients with faecal incontinence (FI) and may be effective in selected patients; however, its mechanism of action is unknown. We sought to determine the effects of PTNS on anorectal physiological parameters. Methods: Fifty patients with FI underwent 30 min of PTNS treatment, weekly for 12 weeks. High-resolution anorectal manometry, bowel diaries and Vaizey questionnaires were performed before and after treatment...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30034532/tenofovir-alafenamide-in-the-treatment-of-chronic-hepatitis-b-virus-infection-rationale-and-clinical-trial-evidence
#19
REVIEW
Ruth Byrne, Ivana Carey, Kosh Agarwal
Tenofovir alafenamide (TAF), a novel prodrug of tenofovir was developed to deliver enhanced antiviral potency and reduced systemic toxicities by more efficient intracellular delivery of the active metabolite tenofovir disphosphate than tenofovir disoproxil fumarate (TDF). In two randomized, double-blind, multinational phase III trials in patients with hepatitis B e antigen (HBeAg)-positive or -negative infection, TAF 25 mg was non-inferior to TDF 300 mg in achieving the primary efficacy outcome of a hepatitis B virus (HBV) DNA level < 29 IU/ml at week 48 and was associated with higher rates of alanine aminotransferase (ALT) normalization based on AASLD (American Association for the Study of Liver Diseases) criteria...
2018: Therapeutic Advances in Gastroenterology
https://www.readbyqxmd.com/read/30034531/one-step-endoscopic-ultrasound-guided-management-of-pelvic-abscesses-a-case-series
#20
Zachary Zator, Matthew Klinge, Wolfgang Schraut, Allan Tsung, Asif Khalid
Background: Endoscopic management of pelvic abscesses not amenable to percutaneous drainage has been described. The technique employs endoscopic ultrasound (EUS)-guided placement of stents or drains, which may require multiple procedures, is cumbersome and uncomfortable for the patient. We describe the successful management of these abscesses in a single step involving EUS-guided lavage and instillation of antibiotics. Methods: Six consecutive patients with seven symptomatic pelvic abscesses not amenable to percutaneous drainage were referred for EUS-guided drainage...
2018: Therapeutic Advances in Gastroenterology
journal
journal
42067
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"